EUCTR2008-003011-12-GB进行中（未招募）1 期
Prospective Randomised Double-Blind Placebo Controlled Study Assessing the Efficacy of Tocilizumab with Synovial Analysis in Patients with Rheumatoid Arthritis - TOCRA
niversity of Leeds0 个研究点目标入组 30 人开始时间: 2009年4月27日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1.Diagnosis of rheumatoid arthritis (1987 revised ACR criteria) confirmed at least 6 months prior to screening. 2.Persistent RA disease activity not responsive (ACR 0 and / or EULAR None-response) whilst being treated with an anti-TNF agent for at least 12 weeks. 3.Patients who have previously discontinued anti-TNF due to toxicity. 4.Patients have previously qualified for anti-TNF (NICE / BSR criteria) but therapy is contra-indicated. 5.Methotrexate dose stable for 12 weeks prior to screening and to be continued for the duration of the study. 6.Subjects with active RA at baseline are defined as: DAS28 > 5.1 7.Female patients will only be enrolled into the study if they are of non child bearing potential (surgically sterile or at least 2 years postmenopausal) or have satisfied the investigator as having an adequate form of contraception. Male patients must consent to practice contraception during the study. 8.Patients on NSAIDs and / or corticosteroids must have remained on an unchanged regimen for at least 28 days prior to study drug administration. 9. Discontinuation of a prohibited DMARD (e.g. oral or injectable gold, chloroquine, hydroxychloroquine, cyclosporine, azathioprine, leflunomide, sulphasalazine) or TNF-blocker (infliximab, etanercept or adalimumab) must occur at least 28 days prior to study drug administration (week 0). 10. Patients must be able and willing to comply with the terms of this protocol including attending for arthroscopy and imaging assessments. 11. Informed consent must be obtained in writing for all subjects at enrolment into the study. 4.3 EXCLUSION CRITERIA 1. Patients unwilling or unable to receive MTX for the duration of the study. 2. Patients with inflammatory joint disease of different origin, mixed connective tissue disease, Reiter’s syndrome, psoriatic arthritis, systemic lupus erythematosus, or any arthritis with onset prior to 16 years of age. 3. Suspicion of diagnosis of tuberculosis (positive tuberculosis test (>5mm induration if previous BCG or >10mm if no previous BCG) or abnormal chest x-ray)…
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 0
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 0
排除标准
- •1. Patients unwilling or unable to receive MTX for the duration of the study. 2. Patients with inflammatory joint disease of different origin, mixed connective tissue disease, Reiter’s syndrome, psoriatic arthritis, systemic lupus erythematosus, or any arthritis with onset prior to 16 years of age. 3. Suspicion of diagnosis of tuberculosis (positive tuberculosis test (>5mm induration if previous BCG or >10mm if no previous BCG) or abnormal chest x-ray). 4. Patients with concomitant medical condition which would in the investigator’s opinion compromise the patient’s ability to tolerate, absorb, metabolise or excrete the study medication. 5. Patients with serious infections within 3 month of enrolment (screening) or persistent infections. 6. Patients at significant risk of infection (e.g. leg ulceration, indwelling urinary catheter, septic joint within 1 year (or ever if prosthetic joint still in situ)). 7. Patients with malignancy (other than excised basal cell carcinoma) within the last 5 years before study entry (screening). 8. Patients with history of Felty’s syndrome, uncontrolled diabetes, uncontrolled hypertension, unstable ischaemic heart disease, active bowel disease, active peptic ulcer disease, recent stroke (within three month before study entry (screening)), or other condition which, in the opinion of the investigator, would put the patient at risk to participate in the study. 9. Known positive serology for hepatitis B or C, or HIV 10. Patients with acute major trauma. 11. Patients with body weight < 45 kg. 12. Clinically relevant cardiovascular, hepatic, neurologic (such as multiple sclerosis, optic neuritis etc.), endocrine, or other major systemic disease making implementation of the protocol or interpretation of the study results difficult. 13. Impaired hepatic function, as shown by • ALT or ALP ? 2 times the laboratory upper limit of normal or • Serum albumin < 30 g/l. 14. Patients with significantly impaired bone marrow function as for example significant anaemia, leukopenia, neutropenia or thrombocytopenia as shown by the following laboratory values : • Haemoglobin < 8.5 g/dl • Hematocrit < 30% • Platelet count < 100 x 109 / L • White blood cell count < 3.5 x 109 / L • Neutrophils count < 1 x 109 / L 15. Patients with severe hypoproteinaemia, e.g. in nephrotic syndrome or impaired renal function, as shown by: • Serum Creatinine > 150 umol / L • Creatinine Clearance ? 50 ml/min 16. Therapy within the previous 28 days before study drug administration with: • Other biological agents, e.g. anti-TNF, interferon, monoclonal antibodies, growth factor, cytokines. • Other DMARDs (e.g. oral or injectable gold, chloroquine, hydroxychloroquine, cyclosporine, azathioprine, leflunomide, sulfasalazine, D-penicillamine, alkylating agents, e.g. cyclophosphamide, chlorambucil) 17. Doses of prednisolone > 10mg/d within the previous 28 days before study drug administration (week 0). 18. Intra-articular or intra-muscular steroid administration within 28 days before screening. Intra-articular steroid into joint to be scanned / biopsied within 12 weeks of baseline assessments. 19. Previous treatment with total lymphoid irradiation or anti - CD4 or CAMPATH 1-H monoclonal antibodies, resulting in CD4-Lymphopenia and possible immunosuppression (CD4 lymphocytes < 500/mm3). 20. Pregnant women or women of childbearing potential. Pregnancy must be excluded before start of treatment with the study drug. 21. Women who are Breast-fe
研究者
相似试验
招募中
不适用
Trial on the efficacy of metformin in the treatment of Non-alcoholic steatohepatitison - alcoholic steatohepatitis (NASH)SLCTR/2007/002Faculty of Medicine, University of Kelaniya,170
进行中（未招募）
1 期
Randomized, prospective double-blind placebo controlled study for the evaluation of the number, duration and severity of Upper Respiratory Tract Infections in children with risk of recurrence after standard treatment with bacterial lysates Paspat 3 mg tablets, over an observation period of six months.upper respiratory tract infections in children at high risk of reccurence.EUCTR2016-000979-24-ITDaiichi Sankyo Italia SpA210
进行中（未招募）
1 期
Randomized, prospective double-blind placebo controlled study for the evaluation of the number, duration and severity of Respiratory Tract Infections in adults with risk of recurrence after standard treatment with bacterial lysates Paspat 3 mg tablets, over an observation period of six months.EUCTR2016-000978-38-ITDAIICHI SANKYO ITALIA S.P.A.210
已完成
不适用
Midazolam at end of the surgery - does it prevent emergence agitation?CTRI/2018/09/015790Hinduja National Hospital64
进行中（未招募）
1 期
A Prospective Double-blind Placebo Controlled Randomised Trial of Intravenous Iron Supplementation in Patients Undergoing Colorectal Cancer Surgery - RCT IV iron in colorectal cancer patientsEUCTR2005-003608-13-GBPlymouth Hospitals NHS Trust126